EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma

Susanne Koeppen, Jörg Hense, Kay Wilhelm Nolte, Joachim Weis

Archives of Pathology and Clinical Research · 2022

DOI: 10.29328/journal.apcr.1001028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Pathology and Clinical Research, 2022. Verfasst von Susanne Koeppen und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment options in multiple myeloma (MM) based on novel agents are often limited by dose-related neurotoxicity. Bortezomib, a highly active reversible proteasome inhibitor, frequently causes peripheral neuropathy (PN). Bortezomib-induced PN (BIPN) is characterized by a length-dependent, sensory, axonal polyneuropathy (PNP) with predominant small fiber-affection. Following dose reduction or drug discontinuation, BIPN resolves within 3-4 months in the majority of patients. The pathophysiological mechanisms of BIPN are unclear. Rare cases of a severe demyelinating or mixed BIPN with prominent motor involvement have been attributed to autoimmune or inflammatory reactions. A case report, including nerve pathology, is presented of a 59-year-old man with stage III IgG-κ MM who was treated with bortezomib on the occurrence of progressive disease. After the fourth cycle, he developed a painful distal symmetric sensory PNP followed by gait instability and muscle weakness increasing over 3 months despite early cessation of bortezomib. Neurological examination revealed a distal flaccid tetraparesis mainly of the lower limbs with sensory loss and severe ataxia, electrophysiological features of a mixed axonal-demyelinating PNP, and pathomorphological evidence of neuritis. Steroid treatment was initiated, and partial recovery of the neurological symptoms within 6 months was observed. While a neurotoxic effect may explain the initial distal sensory disturbances, the worsening of neurological dysfunction after bortezomib withdrawal and the clinical pattern with steroid-responsive muscle weakness predominantly of the legs are consistent with an immune-mediated mechanism. This is in line with the sural nerve biopsy findings. Toxic BIPN followed by an immune-mediated BIPN in the same patient has not been reported before.

Zitieren

APA

Koeppen, S., Hense, J., Nolte, K. W., & Weis, J. (2022). Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma. Archives of Pathology and Clinical Research. https://doi.org/10.29328/journal.apcr.1001028

Vancouver

Koeppen S, Hense J, Nolte KW, Weis J. Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma. Archives of Pathology and Clinical Research. 2022. doi:10.29328/journal.apcr.1001028

BibTeX
@article{Koeppen2022,
  author = {Koeppen, Susanne and Hense, Jörg and Nolte, Kay Wilhelm and Weis, Joachim},
  title = {Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma},
  journal = {Archives of Pathology and Clinical Research},
  year = {2022},
  doi = {10.29328/journal.apcr.1001028}
}
Kostenlos starten →